sequence under fasting conditions and at least 14 days washout period between the doses.,A randomized&#44

Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Rosuvastatin Tablets (20 mg) relative to Crestor (Original Rosuvastatin Tablets (20 mg)) in healthy Thai volunteers under fasting condition

A Bioequivalence study of a randomized, open-label, single-dose, two-way crossover design with two-period, two-treatment and two-sequence of Quetiapine 200 mg immediate release tablets imported by Great Eastern Drug Co., Ltd., (hereinafter referred to as “Tested Preparation”) relative to Seroquel 200 mg tablets, (hereinafter referred to as “Reference Preparation”) in healthy Thai volunteers under fasting condition

A Bioequivalence study of a randomized, open-label, single-dose, two-way crossover design with two-period, two-treatment and two-sequence of Etoricoxib 120 mg film-coated tablets relative to Arcoxia® 120 mg film-coated tablets in healthy Thai volunteers under fasting conditions

Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Levonorgestrel Tablets (1.5 mg) relative to POSTINOR ONE® in healthy Thai female volunteers under fasting condition

A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Etoricoxib 120 mg tablets relative to Arcoxia(R) 120 mg tablets in healthy Thai volunteers under fasting condition

Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Escitalopram Tablet (20 mg) relative to Lexapro(R) in healthy Thai volunteers under fasting condition